EHA 2026: MRD-Negative Responses And Outcomes After VRD Induction And Transplant In Newly Diagnosed Multiple Myeloma

In this MEDtalk, Frida Bugge Askeland, MD and consultant physician at Oslo Myeloma Center, Oslo University Hospital, presents results from the phase 2 part of the REMNANT trial in newly diagnosed transplant-eligible multiple myeloma patients. The study evaluated VRD induction, single or tandem transplant, and consolidation with MRD assessment after treatment. The results show MRD-negative complete responses and favorable progression-free and overall survival across age groups in a real-world population.